HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sally Kilbride Selected Research

GSK573719

1/2021Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
1/2021Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
1/2021Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
11/2020The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
6/2020Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
1/2020Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
1/2020The effect of exacerbation history on outcomes in the IMPACT trial.
1/2020Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
1/2020Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
1/2019The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sally Kilbride Research Topics

Disease

20Chronic Obstructive Pulmonary Disease (COPD)
03/2022 - 10/2012
3Pneumonia (Pneumonitis)
01/2021 - 10/2017
1Cardiovascular Diseases (Cardiovascular Disease)
06/2020
1Dyspnea (Shortness of Breath)
05/2014

Drug/Important Bio-Agent (IBA)

18vilanterolIBA
01/2021 - 04/2013
15fluticasone furoateFDA Link
01/2021 - 04/2013
14GSK573719IBA
01/2021 - 05/2014
4Bronchodilator Agents (Bronchodilators)IBA
01/2019 - 10/2012
3Adrenal Cortex Hormones (Corticosteroids)IBA
01/2021 - 01/2017
2Muscarinic AntagonistsIBA
05/2018 - 10/2012
1Anti-Bacterial Agents (Antibiotics)IBA
01/2021
1omega-Chloroacetophenone (Mace)IBA
06/2020
1GlucocorticoidsIBA
05/2018
1Albuterol (Salbutamol)FDA LinkGeneric
05/2014
1Cholinergic Antagonists (Anticholinergics)IBA
10/2012

Therapy/Procedure

13Therapeutics
03/2022 - 04/2013
9Nebulizers and Vaporizers (Inhaler)
03/2022 - 05/2018